Drug Trial Radar · NCT04679935
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jul 13, 2021
Primary completion
Jan 31, 2024
Study completion Jan 31, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received anti-VEGF (vascular endothelial growth factor) treatment.
Conditions
- Age-related Macular Degeneration
Interventions
BrolucizumabBiological
Intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Week 40 to Week 52: LS Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study EyeTime frame: Baseline, Week 40 to Week 52
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Düsseldorf, Germany
Novartis Investigative Site
Göttingen, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Homburg, Germany
Novartis Investigative Site
Leipzig, Germany
Novartis Investigative Site
Lübeck, Germany
Novartis Investigative Site
Magdeburg, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Marburg, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Neubrandenburg, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Regensburg, Bavaria, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Bern, Switzerland
Novartis Investigative Site
Zurich, Switzerland
Novartis Investigative Site
Lausanne, CHE, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.